Genenta Science S.p.A. GNTA
Genenta Science S.p.A. (Nasdaq: GNTA) is an oncology drug developer. Its lead program, Temferon, is in Phase 1 for Newly diagnosed unmethylated MGMT glioblastoma multiforme (TEM-GBM).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Temferon (TEM-GBM Phase 1/2a) | Glioblastoma multiforme; enrollment completed, preliminary results encouraging but no efficacy claim possible | gene therapy | Phase 1 |
| Temferon (TEM-GU Phase 1) | Metastatic renal cell carcinoma; program discontinued January 2026 | gene therapy | Phase 1 |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.